STXS

Stereotaxis is a genuine but perpetually unprofitable medical-robotics story. FY2025 revenue rose 20.3% to $32.4M with a healthy 52.7% gross margin, and the MD&A's GenesisX RMN — pitched as reducing the 'lengthy construction cycle' of prior systems — plus 150,000+ patients and 500+ publications give the technology real clinical validation. But after five straight years of losses (net income -$21.6M in FY2025, operating margin -68.3%, ROE -160.5%) and a $583M accumulated deficit, the investment case rests on balance-sheet survival, and that is where it breaks down.

The decisive number is liquidity: $13.4M of cash against $13.7M of operating cash burn that worsened 61% year over year. That is roughly twelve months of runway before financing is required, and management has already leaned on dilution — shares outstanding grew 13.1% in FY2025. A near-term capital raise at a $1.79 microcap price is close to a base case, not a tail risk, and it caps upside for existing holders. Stockholders' equity of $13.5M looks thin and flatters the picture only because the deficit is carried against paid-in capital.